Locomotor effects of imidazoline I2 -site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway-Reference-Cited by-同舟云学术

Locomotor effects of imidazoline I2 -site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway

Published:2004-12 Issue:8 Volume:143 Page:952-959
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:

Author:

MacInnes Nicholas,Duty Susan

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1038/sj.bjp.0706019/fullpdf

Reference47 articles.

1. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors;ALEMANY;Br. J. Pharmacol.,1995

2. New developments SL25.1131, a new, reversible and mixed inhibitor of MAO-A and MAO-B: biochemical and behavioural profile;AUBIN;J. Pharmacol. Exp. Ther.,2004

3. The use of L-DOPA in Parkinson's disease: a 20 year follow up;BARBEAU;Trends Pharmacol. Sci.,1981

4. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A;BURKWARD;J. Pharmacol. Exp. Ther.,1989

5. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum;BUTCHER;J. Neurochem.,1990

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of Imidazoline Related Corrosion Inhibitor on Corrosion of Carbon-Steels;Zairyo-to-Kankyo;2022-06-10

2. 6-Hydroxydopamine: a far from simple neurotoxin;Journal of Neural Transmission;2020-01-01

3. Neuroanatomical characterization of imidazoline I2 receptor agonist-induced antinociception;European Journal of Neuroscience;2018-03-23

4. The effect of Banisteriopsis caapi (B. caapi ) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease;Phytotherapy Research;2018-01-24

5. A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties;European Journal of Pharmacology;2018-01